Table 1 Clinical characteristics of the study cohorts
From: Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression
Characteristic | Â |
|---|---|
Localized prostate cancer cohort | |
 Patients, n | 458 |
 Age at diagnosis | |
  Median, years (IQR) | 66 (61–70) |
 PSA at diagnosis | |
  Median, ng/mL (IQR) | 11.1 (7.1–17.5) |
 Pathologic Gleason score, n (%) | |
  < 7 | 160 (35.3) |
  7 | 232 (51.2) |
  > 7 | 61 (13.5) |
 Pathologic stage, n (%) | |
  T1/T2 | 303 (67.2) |
  T3/T4/N1 | 148 (32.8) |
  M1 | 0 (0.0) |
 Disease progression | |
  No | 274 (59.8) |
  Yes | 184 (40.2) |
Advanced prostate cancer cohort | |
 Patients, n | 324 |
 Age at diagnosis | |
  Median, years (IQR) | 72 (66–78) |
 PSA at ADT initiation | |
  Median, ng/mL (IQR) | 32.6 (9.4–123.4) |
 Biopsy Gleason score at diagnosis, n (%) | |
  < 7 | 70 (22.2) |
  7 | 131 (41.5) |
  > 7 | 115 (36.4) |
 Clinical stage at diagnosis, n (%) | |
  T1/T2 | 92 (28.6) |
  T3/T4/N1 | 103 (32.0) |
  M1 | 127 (39.4) |
 PSA nadir | |
  Median, ng/mL (IQR) | 0.12 (0.01–1.08) |
 Treatment modality | |
  ADT as primary treatment | 138 (42.7) |
  ADT for post RP PSA failure | 39 (12.1) |
  ADT for post RT PSA failure | 6 (1.9) |
  Neoadjuvant/adjuvant ADT with RT | 101 (31.3) |
  Others | 39 (12.1) |
 Disease progression | |
  No | 28 (8.6) |
  Yes | 296 (91.4) |